Obesity
Weight Loss "World War II" : Beyond Ozempic and Mounjaro
The $1 trillion battleground where pharma giants and scrappy biotechs are fighting for supremacy — and why the real winners may be patients who couldn't afford these drugs before.
Latest
JANX
Janux Therapeutics ($JANX): The "Pluvicto Killer" Thesis Is Alive, But the Hype Had to Die First
In the high-stakes world of biotechnology, "good" is often not enough when the market is pricing in "perfection." Yesterday, Janux Therapeutics ($JANX) released updated Phase 1 data that triggered a sharp >40% sell-off. The market’s simplistic algorithm—"No massive beat on the headline
🧬 BIOTECH CATALYST AI SCANNER — December WK1
The XBI just logged a +10.72% gain over 21 days—and the beaten-down clinical-stage names are stirring. This week's scanner combed through 250+ catalyst events expected within 10-45 days. What jumps off the screen? Eight companies currently trade below their cash balances. The market has essentially written
Catalyst
The Biotech Edge: Analyzing 8,000 Catalysts to Find the Alpha
Data-driven biotech investing: Biostockinfo reveals how clinical catalysts, anticipation run-ups and Breakthrough Therapy designations create alpha for independent retail investors.
🧬 BIOTECH CATALYST AI SCANNER — November WK4
I apologize for the delay in this week’s AI Scanner. I’ve been working on using newly updated Gemini 3.0, which was supposed to be superior. However, the results were mixed, and it took some time to debug the system. This AI Scanner is still work in progress,
INAB
IN8bio ($INAB) : Undervalued Oncology Play or Capital Crunch Disaster?
Is this a value trap headed for dilution and oblivion—or a deeply mispriced recovery play for investors who can live with binary risk?
AI
🧬 BIOTECH CATALYST AI SCANNER — November WK3
After an extremely tough week for the biotech sector—and the broader market—we're finally seeing signs of recovery. With the government shutdown issue now resolved, the sector should hopefully regain momentum in the coming weeks. From last week's top 15 picks, IFRX and GLTO showed
Biotech Investing
The Retail Investor's Blueprint for Biotech: From Lead Generation to Exit Strategy
Biotech investing looks chaotic from the outside, but retail investors can compete with PhDs by using a disciplined framework, understanding risk, and defining clear exits so they play a game of skill, not luck.
MLTX
MoonLake ($MLTX): From Collapse to Recovery Play—The Nanobody Rebound Story
The Fall from Grace: A 90% Overnight Collapse On September 28, 2025, MoonLake Immunotherapeutics (NASDAQ: MLTX) experienced one of biotech's most dramatic single-day collapses in recent memory. The stock plummeted 90%—from $62 to as low as $5.95—as the company announced results from its Phase 3
AI
🧬 BIOTECH CATALYST AI SCANNER — November WK2
Here are the biotech catalyst AI scanner results for the second week of November. This past week has been particularly challenging for many biotechs, especially in the rare disease sector, where numerous setbacks have negatively impacted market sentiment. General market volatility and a noticeable friction between the FDA and the
Rare Disease
From Boom to Regulatory Bust? The Evolving Landscape for Rare Genetic Disease Therapies
Explore the volatile world of rare disease biotechs in 2025, from Novartis's $12B Avidity acquisition sparking optimism to FDA scrutiny causing stock plunges for uniQure and Sarepta.
Guide
The Biotech Investor's Compass: Navigating Risk in a Field of Uncertainty
Standard valuation metrics fail in biotech. Success requires different frameworks. I'll share my approaches—wins, losses, and lessons learned.